UNSPSC 51152034: Lanperisone

This classification denotes a muscle relaxant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TO2JP2G53H. European Medicines Agency schedules Lanperisone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08400MIG. Lanperisone generally arises in the molecular formula C15H18F3NO.

UNSPSC 51152034 Lanperisone, a Commodity code, tracks pharmaceutical muscle relaxants and pain-management medications that state and local health agencies procure for community health programs, emergency response, and clinical settings. Recent state and local solicitations under this code show demand for naloxone and drug deactivation systems as part of broader public-health and opioid-response initiatives, though the specific pharmaceutical scope of the code itself appears narrower than the range of health-related products agencies are tagging to it.

Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023. The solicitation required electronic submission through the county's e-Procurement Portal, E-Verify compliance, drug-free workplace certification, and standard commercial insurance (workers' compensation, commercial general liability, professional liability); the contract carried a two-year initial term with a one-year renewal option and a three-month probationary termination clause. Potential FEMA funding introduced compliance with the Clean Air Act and Federal Water Pollution Control Act. The source provides no additional recent opportunities under the code, limiting visibility into geographic spread or the broader issuing-body mix soliciting lanperisone or closely related pharmaceuticals across state and local jurisdictions.